TGF-β negatively regulates CXCL1 chemokine expression in mammary fibroblasts through enhancement of smad2/3 and suppression of HGF/c-met signaling mechanisms

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Fang, Wei Bin ^a   Mafuvadze, Benford ^a   Yao, Min ^a   Zou, An ^a   Portsche, Mike ^a   Cheng, Nikki ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CXCL1 CHEMOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SMAD2 PROTEIN; SMAD3 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA; CXCL1 PROTEIN, HUMAN; CXCL1 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL CELL; ARTICLE; AUTOCRINE EFFECT; BINDING SITE; CANCER CELL LINE; CARCINOMA ASSOCIATED FIBROBLAST; CONTROLLED STUDY; DOWN REGULATION; FIBROBLAST; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAMMARY FIBROBLAST; MOUSE; NONHUMAN; POINT MUTATION; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION; ANIMAL; BREAST; C57BL MOUSE; CYTOLOGY; FEMALE; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY; SITE DIRECTED MUTAGENESIS; TUMOR CELL CULTURE; UDDER;

ANIMALS; BREAST; CARCINOMA, DUCTAL, BREAST; CHEMOKINE CXCL1; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION; HEPATOCYTE GROWTH FACTOR; HUMANS; MAMMARY GLANDS, ANIMAL; MICE; MICE, INBRED C57BL; MUTAGENESIS, SITE-DIRECTED; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MET; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR CELLS, CULTURED;

EID: 84941946054     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0135063     Document Type: Article

References (74)

1. Valluru M, Staton CA, Reed MW, Brown NJ. Transforming Growth Factor-beta and Endoglin Signaling Orchestrate Wound Healing. Frontiers in physiology. 2011; 2:89. Epub 2011/12/14. doi: 10.3389/fphys. 2011.00089 PMID: 22164144; PubMed Central PMCID: PMC3230065
2. Shinde AV, Frangogiannis NG. Fibroblasts in myocardial infarction: A role in inflammation and repair. Journal of molecular and cellular cardiology. 2014; 70:74-82. doi: 10.1016/j.yjmcc.2013.11.015 PMID: 24321195
3. Polanska UM, Orimo A. Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. J Cell Physiol. 2013; 228(8):1651-7. doi: 10.1002/jcp.24347 PMID: 23460038
4. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006; 6(5):392-401. Epub 2006/03/31. doi: 10.1038/nrc1877 PMID: 16572188
5. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005; 121(3):335-48. Epub 2005/05/11. doi: 10.1016/j.cell. 2005.02.034 PMID: 15882617
6. Jedeszko C, Victor BC, Podgorski I, Sloane BF. Fibroblast hepatocyte growth factor promotes invasion of human mammary ductal carcinoma in situ. Cancer Res. 2009; 69(23):9148-55. Epub 2009/11/19. 0008-5472.CAN-09-1043 [pii] doi: 10.1158/0008-5472.CAN-09-1043 PMID: 19920187
7. Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld RA. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One. 2009; 4(11):e7965. Epub 2009/12/04. doi: 10.1371/journal.pone.0007965 PMID: 19956757; PubMed Central PMCID: PMC2775953
8. Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A. 2004; 101(14):4966-71. doi: 10.1073/pnas.0401064101 PMID: 15051869; PubMed Central PMCID: PMC387357
9. Sadlonova A, Mukherjee S, Bowe DB, Gault SR, Dumas NA, Van Tine BA, et al. Human breast fibroblasts inhibit growth of the MCF10AT xenograft model of proliferative breast disease. Am J Pathol. 2007; 170(3):1064-76. doi: 10.2353/ajpath.2007.060031 PMID: 17322389; PubMed Central PMCID: PMC1864888
10. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008; 14(5):518-27. Epub 2008/04/29. doi: 10.1038/ nm1764 PMID: 18438415
11. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004; 6(1):17-32. PMID: 15261139
12. Frings O, Augsten M, Tobin NP, Carlson J, Paulsson J, Pena C, et al. Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling. Am J Pathol. 2013; 182(6):2037-47. doi: 10.1016/j.ajpath.2013.02.018 PMID: 23583284
13. Zaja-Milatovic S, Richmond A. CXC chemokines and their receptors: a case for a significant biological role in cutaneous wound healing. Histology and histopathology. 2008; 23(11):1399-407. PMID: 18785122; PubMed Central PMCID: PMC3140405
14. Kobayashi Y. The role of chemokines in neutrophil biology. Front Biosci. 2008; 13:2400-7. PMID: 17981721
15. Dhawan P, Richmond A. Role of CXCL1 in tumorigenesis of melanoma. J Leukoc Biol. 2002; 72(1):9-18
16. Miyake M, Lawton A, Goodison S, Urquidi V, Rosser CJ. Chemokine (C-X-C motif) ligand 1 (CXCL1) protein expression is increased in high-grade prostate cancer. Pathology, research and practice. 2013. Epub 2013/11/21. doi: 10.1016/j.prp.2013.08.013 PMID: 24252309
17. Kawanishi H, Matsui Y, Ito M, Watanabe J, Takahashi T, Nishizawa K, et al. Secreted CXCL1 is a potential mediator and marker of the tumor invasion of bladder cancer. Clin Cancer Res. 2008; 14 (9):2579-87. Epub 2008/05/03. doi: 10.1158/1078-0432.CCR-07-1922 PMID: 18451219
18. Vazquez-Martin A, Colomer R, Menendez JA. Protein array technology to detect HER2 (erbB-2)- induced 'cytokine signature' in breast cancer. Eur J Cancer. 2007; 43(7):1117-24. PMID: 17379503
19. Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 2012; 150(1):165-78. Epub 2012/07/10. doi: 10.1016/j.cell.2012.04.042 PMID: 22770218; PubMed Central PMCID: PMC3528019
20. Zou A, Lambert D, Yeh H, Yasukawa K, Behbod F, Fan F, et al. Elevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-beta signaling proteins. BMC Cancer. 2014; 14:781. doi: 10.1186/1471-2407-14-781 PMID: 25344051; PubMed Central PMCID: PMC4221705
21. Zu X, Zhang Q, Cao R, Liu J, Zhong J, Wen G, et al. Transforming growth factor-beta signaling in tumor initiation, progression and therapy in breast cancer: an update. Cell and tissue research. 2012; 347 (1):73-84. Epub 2011/08/17. doi: 10.1007/s00441-011-1225-3 PMID: 21845401
22. Derynck R, Muthusamy BP, Saeteurn KY. Signaling pathway cooperation in TGF-beta-induced epithelial- mesenchymal transition. Curr Opin Cell Biol. 2014; 31:56-66. doi: 10.1016/j.ceb.2014.09.001 PMID: 25240174
23. Calon A, Tauriello DV, Batlle E. TGF-beta in CAF-mediated tumor growth and metastasis. Semin Cancer Biol. 2014; 25:15-22. doi: 10.1016/j.semcancer.2013.12.008 PMID: 24412104
24. Pickup M, Novitskiy S, Moses HL. The roles of TGFbeta in the tumour microenvironment. Nat Rev Cancer. 2013; 13(11):788-99. doi: 10.1038/nrc3603 PMID: 24132110
25. Cheng N, Bhowmick NA, Chytil A, Gorksa AE, Brown KA, Muraoka R, et al. Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene. 2005; 24(32):5053-68. Epub 2005/04/28. doi: 10.1038/sj.onc.1208685 PMID: 15856015; PubMed Central PMCID: PMC3074577
26. Cheng N, Chytil A, Shyr Y, Joly A, Moses HL. Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis. Cancer Res. 2007; 67(10):4869-77. Epub 2007/05/15. doi: 10.1158/0008-5472.CAN-06-3381 PMID: 17495323
27. Cheng N, Lambert DL. Mammary transplantation of stromal cells and carcinoma cells in C57BL/6J mice. Journal of visualized experiments: JoVE. 2011;(54: ). Epub 2011/08/24. doi: 10.3791/2716 PMID: 21860377
28. Fang WB, Jokar I, Chytil A, Moses HL, Abel T, Cheng N. Loss of one Tgfbr2 allele in fibroblasts promotes metastasis in MMTV: polyoma middle T transgenic and transplant mouse models of mammary tumor progression. Clin Exp Metastasis. 2011; 28(4):351-66. Epub 2011/03/05. doi: 10.1007/s10585- 011-9373-0 PMID: 21374085
29. Dandekar DH, Ganesh KN, Mitra D. HIV-1 Tat directly binds to NFkappaB enhancer sequence: role in viral and cellular gene expression. Nucleic Acids Res. 2004; 32(4):1270-8. doi: 10.1093/nar/gkh289 PMID: 14981150; PubMed Central PMCID: PMC390279
30. Wrana JL, Attisano L, Carcamo J, Zentella A, Doody J, Laiho M, et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell. 1992; 71(6):1003-14. Epub 1992/12/11. 0092-8674 (92)90395-S [pii]. PMID: 1333888
31. Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, et al. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science. 2005; 310(5755):1817-21. Epub 2005/ 11/26. doi: 10.1126/science.1121158 PMID: 16308420
32. Henningfeld KA, Rastegar S, Adler G, KnochelW. Smad1 and Smad4 are components of the bone morphogenetic protein-4 (BMP-4)-induced transcription complex of the Xvent-2B promoter. J Biol Chem. 2000; 275(29):21827-35. doi: 10.1074/jbc.M000978200 PMID: 10791953
33. Krieg RC, Fogt F, Braunschweig T, Herrmann PC, Wollscheidt V, Wellmann A. ProteinChip Array analysis of microdissected colorectal carcinoma and associated tumor stroma shows specific protein bands in the 3.4 to 3.6 kDa range. Anticancer Res. 2004; 24(3a):1791-6. PMID: 15274357
34. Grantab RH, Tannock IF. Penetration of anticancer drugs through tumour tissue as a function of cellular packing density and interstitial fluid pressure and its modification by bortezomib. BMC Cancer. 2012; 12:214. doi: 10.1186/1471-2407-12-214 PMID: 22672469; PubMed Central PMCID: PMC3407510
35. Frederick JP, Liberati NT, Waddell DS, Shi Y, Wang XF. Transforming growth factor beta-mediated transcriptional repression of c-myc is dependent on direct binding of Smad3 to a novel repressive Smad binding element. Mol Cell Biol. 2004; 24(6):2546-59. Epub 2004/03/03. PMID: 14993291
36. Massague J. TGF-b signaling in context. Nat Rev Mol Cell biol. 2012; 13(10):616-30. doi: 10.1038/ nrm3434 PMID: 22992590
37. Heldin CH, Moustakas A. Role of Smad in TGF-b signaling. Cell and tissue research. 2012; 347(1):21-36. doi: 10.1007/s00441-011-1190-x PMID: 21643690
38. Shi Y, Wang YF, Jayaraman L, Yang H, Massague J, Pavletich NP. Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. Cell. 1998; 94(5):585-94. Epub 1998/09/19. PMID: 9741623
39. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, Vogelstein B, et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell. 1998; 1(4):611-7. PMID: 9660945
40. Choy L, Derynck R. Transforming growth factor-beta inhibits adipocyte differentiation by Smad3 interacting with CCAAT/enhancer-binding protein (C/EBP) and repressing C/EBP transactivation function. J Biol Chem. 2003; 278(11):9609-19. doi: 10.1074/jbc.M212259200 PMID: 12524424
41. Coyle-Rink J, Sweet T, Abraham S, Sawaya B, Batuman O, Khalili K, et al. Interaction between TGFbeta signaling proteins and C/EBP controls basal and Tat-mediated transcription of HIV-1 LTR in astrocytes. Virology. 2002; 299(2):240-7. PMID: 12202226
42. Marchildon F, St-Louis C, Akter R, Roodman V, Wiper-Bergeron NL. Transcription Factor Smad3 Is Required for the Inhibition of Adipogenesis by Retinoic Acid. The Journal of Biological Chemistry. 2010; 285(17):13274-84. doi: 10.1074/jbc.M109.054536. PMC2857127. PMID: 20179325
43. Mueller KL, Madden JM, Zoratti GL, Kuperwasser C, List K, Boerner JL. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triplenegative breast cancers through paracrine activation of Met. Breast Cancer Res. 2012; 14(4):R104. doi: 10.1186/bcr3224 PMID: 22788954; PubMed Central PMCID: PMC3680928
44. Cheng N, Chytil A, Shyr Y, Joly A, Moses HL. Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte growth factor signaling in mammary carcinoma cells to promote scattering and invasion. Mol Cancer Res. 2008; 6(10):1521-33. Epub 2008/10/17. doi: 10.1158/1541-7786.MCR- 07-2203 PMID: 18922968; PubMed Central PMCID: PMC2740918
45. Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, Hortobagyi GN, et al. cMET and phospho- cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res. 2012; 18(8):2269-77. Epub 2012/03/01. doi: 10.1158/1078-0432.CCR-11-2830 PMID: 22374333
46. Kawaguchi Y, Harigai M, Hara M, Fukasawa C, Takagi K, Tanaka M, et al. Expression of hepatocyte growth factor and its receptor (c-met) in skin fibroblasts from patients with systemic sclerosis. J Rheumatol. 2002; 29(9):1877-83. Epub 2002/09/18. PMID: 12233882
47. Lin YM, Huang YL, Fong YC, Tsai CH, Chou MC, Tang CH. Hepatocyte growth factor increases vascular endothelial growth factor-A production in human synovial fibroblasts through c-Met receptor pathway. PLoS One. 2012; 7(11):e50924. Epub 2012/12/05. doi: 10.1371/journal.pone.0050924 PMID: 23209838; PubMed Central PMCID: PMC3508989
48. Offersen BV, Nielsen BS, Hoyer-Hansen G, Rank F, Hamilton-Dutoit S, Overgaard J, et al. The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am J Pathol. 2003; 163(5):1887-99. doi: 10.1016/S0002-9440(10)63547-X PMID: 14578188; PubMed Central PMCID: PMC1892443
49. Vered M, Dobriyan A, Dayan D, Yahalom R, Talmi YP, Bedrin L, et al. Tumor-host histopathologic variables, stromal myofibroblasts and risk score, are significantly associated with recurrent disease in tongue cancer. Cancer science. 2010; 101(1):274-80. doi: 10.1111/j.1349-7006.2009.01357.x PMID: 19804423
50. Longati P, Bardelli A, Ponzetto C, Naldini L, Comoglio PM. Tyrosines 1234-1235 are criticasl for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor). Oncogene. 1994; 9 (1):49-57. PMID: 8302603
51. Follenzi A, Bakovic S, Gual P, Stella MC, Longati P, Comoglio PM. Cross-talk between the proto-oncogenes Met and Ron. Oncogene. 2000; 19(27):3041-9. PMID: 10871856
52. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 2003; 63(21):7345-55. PMID: 14612533
53. Puri N, Khramtsov A, Ahmed N, Nallasura V, Hetzel JT, Jagadeeswaran, et al. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenecity and angiogenesis in mouse lung cancer xenogafts. Cancer Res. 2007; 67(8):3529-34. PMID: 17440059
54. Tacchini L, De Ponti C, Matteucci E, Follis R, Desiderio MA. Hepatocyte growth factor-activated NFkappaB regulates HIF-1 activity and ODC expression, implicated in survival, differently in different carcinoma cell lines. Carcinogenesis. 2004; 25(11):2089-100. Epub 2004/07/09. doi: 10.1093/carcin/ bgh227 PMID: 15240510
55. Esencay M, Newcomb EW, Zagzag D. HGF upregulates CXCR4 expression in gliomas via NF-kappaB: implications for glioma cell migration. J Neurooncol. 2010; 99(1):33-40. Epub 2010/02/17. doi:10. 1007/s11060-010-0111-2 PMID: 20157762
56. Damm S, Koefinger P, Stefan M, Wels C, Mehes G, Richtig E, et al. HGF-promoted motility in primary human melanocytes depends on CD44v6 regulated via NF-kappa B, Egr-1, and C/EBP-beta. J Invest Dermatol. 2010; 7(7):1893-903
57. Son DS, Roby KF. Interleukin-1alpha-induced chemokines in mouse granulosa cells: impact on keratinocyte chemoattractant chemokine, a CXC subfamily. Mol Endocrinol. 2006; 20(11):2999-3013. Epub 2006/07/11. doi: 10.1210/me.2006-0001 PMID: 16825293
58. Liu XY, Robinson D, Veach RA, Liu D, Timmons S, Collins RD, et al. Peptide-directed suppression of a pro-inflammatory cytokine response. J Biol Chem. 2000; 275(22):16774-8. doi: 10.1074/jbc. C000083200 PMID: 10751381
59. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, et al. Novel inhibitors of cytokineinduced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show antiinflammatory effects in vivo. J Biol Chem. 1997; 272(34):21096-103. PMID: 9261113
60. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012; 12(2):89-103. Epub 2012/01/25. doi: 10.1038/nrc3205 PMID: 22270953
61. Yang YA, Tang B, Robinson G, Hennighausen L, Brodie SG, Deng CX, et al. Smad3 in the mammary epithelium has a nonredundant role in the induction of apoptosis, but not in the regulation of proliferation or differentiation by transforming growth factor-beta. Cell Growth Differ. 2002; 13(3):123-30. Epub 2002/04/18. PMID: 11959813
62. Miguez DG, Gil-Guinon E, Pons S, Marti E. Smad2 and Smad3 cooperate and antagonize simultaneously in vertebrate neurogenesis. J Cell Sci. 2013. Epub 2013/10/10. doi: 10.1242/jcs.130435 PMID: 24105267
63. Dunn NR, Koonce CH, Anderson DC, Islam A, Bikoff EK, Robertson EJ. Mice exclusively expressing the short isoform of Smad2 develop normally and are viable and fertile. Genes Dev. 2005 19(1):152-63. PMID: 15630024
64. Yagi K GD, Hamamoto T, Takenoshita S, Kato M, Miyazono K. Alternatively spliced variant of Smad2 lacking exon 3. Comparison with wild-type Smad2 and Smad3. J Biol Chem. 1999 274(2):703-9. PMID: 9873005
65. Randall RA, Germain S, Inman GJ, Bates PA, Hill CS. Different Smad2 partners bind a common hydrophobic pocket in Smad2 via a defined proline-rich mo. EMBO J 2002; 15(21):145-56
66. Ou ZL, Wang J, Hou YF, Luo JM, Shen ZZ, Shao ZM. [Downregulation of Duffy antigen receptor for chemokine (DARC) is associated with lymph node metastasis in human breast cancer]. Zhonghua Zhong Liu Za Zhi. 2006; 28(8):586-9. Epub 2007/01/24. PMID: 17236552
67. Fang WB, Jokar I, Zou A, Lambert D, Dendukuri P, Cheng N. CCL2/CCR2 chemokine signaling coordinates survival and motility of breast cancer cells through Smad3 protein- and p42/44 mitogen-activated protein kinase (MAPK)-dependent mechanisms. J Biol Chem. 2012; 287(43):36593-608. doi: 10.1074/ jbc.M112.365999 PMID: 22927430; PubMed Central PMCID: PMC3476325
68. Burke SJ, Lu D, Sparer TE, Masi T, Goff MR, Karlstad MD, et al. NF-kappaB and STAT1 control CXCL1 and CXCL2 gene transcription. American journal of physiology Endocrinology and metabolism. 2014; 306(2):E131-49. doi: 10.1152/ajpendo.00347.2013 PMID: 24280128; PubMed Central PMCID: PMC3920007
69. Wood LD, Farmer AA, Richmond A. HMGI(Y) and Sp1 in addition to NF-kappa B regulate transcription of the MGSA/GRO alpha gene. Nucleic Acids Res. 1995; 23(20):4210-9. PMID: 7479086; PubMed Central PMCID: PMC307364
70. Amiri KI, Ha HC, Smulson ME, Richmond A. Differential regulation of CXC ligand 1 transcription in melanoma cell lines by poly(ADP-ribose) polymerase-1. Oncogene. 2006; 25(59):7714-22. doi: 10.1038/ sj.onc.1209751 PMID: 16799643; PubMed Central PMCID: PMC2665274
71. Yan W, Chen X. Identification of GRO1 as a critical determinant for mutant p53 gain of function. J Biol Chem. 2009; 284(18):12178-87. doi: 10.1074/jbc.M900994200 PMID: 19258312; PubMed Central PMCID: PMC2673286
72. Rahimi N, Saulnier R, Nakamura T, Park M, Elliott B. Role of hepatocyte growth factor in breast cancer: a novel mitogenic factor secreted by adipocytes. DNA Cell Biol. 1994; 13(12):1189-97. Epub 1994/12/01. PMID: 7811385
73. Yamashita J, Ogawa M, Yamashita S, Nomura K, Kuramoto M, Saishoji T, et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res. 1994; 54(7):1630-3. PMID: 8137271
74. Beviglia L, Matsumoto K, Lin CS, Ziober BL, Kramer RH. Expression of the c-Met/HGF receptor in human breast carcinoma: correlation with tumor progression. Int J Cancer. 1997; 74(3):301-9. PMID: 9221809